Octapharma AG - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
37 Pages - GMD12094
$1,500.00

Summary

Global Markets Direct’s, ‘Octapharma AG - Product Pipeline Review - 2014’, provides an overview of the Octapharma AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Octapharma AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Octapharma AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Octapharma AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Octapharma AG’s pipeline products

Reasons to buy

- Evaluate Octapharma AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Octapharma AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Octapharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Octapharma AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Octapharma AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Octapharma AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Octapharma AG Snapshot 5
Octapharma AG Overview 5
Key Information 5
Key Facts 5
Octapharma AG - Research and Development Overview 6
Key Therapeutic Areas 6
Octapharma AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Octapharma AG - Pipeline Products Glance 11
Octapharma AG - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Octapharma AG - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Octapharma AG - Unknown Stage Pipeline Products 14
Unknown Products/Combination Treatment Modalities 14
Octapharma AG - Drug Profiles 15
Human-cl rhFVIII 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
plasma (human) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
immune globulin (human) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
fibrinogen concentrate (human) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Human Growth Factor 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Lyoplas 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NewNorm 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Octapharma AG - Pipeline Analysis 24
Octapharma AG - Pipeline Products by Target 24
Octapharma AG - Pipeline Products by Route of Administration 25
Octapharma AG - Pipeline Products by Molecule Type 26
Octapharma AG - Pipeline Products by Mechanism of Action 27
Octapharma AG - Recent Pipeline Updates 28
Octapharma AG - Dormant Projects 30
Octapharma AG - Company Statement 31
Octapharma AG - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Octapharma AG - Key Manufacturing Facilities 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Octapharma AG, Key Information 5
Octapharma AG, Key Facts 5
Octapharma AG - Pipeline by Indication, 2014 8
Octapharma AG - Pipeline by Stage of Development, 2014 9
Octapharma AG - Monotherapy Products in Pipeline, 2014 10
Octapharma AG - Pre-Registration, 2014 11
Octapharma AG - Phase III, 2014 12
Octapharma AG - Phase II, 2014 13
Octapharma AG - Unknown, 2014 14
Octapharma AG - Pipeline by Target, 2014 24
Octapharma AG - Pipeline by Route of Administration, 2014 25
Octapharma AG - Pipeline by Molecule Type, 2014 26
Octapharma AG - Pipeline Products by Mechanism of Action, 2014 27
Octapharma AG - Recent Pipeline Updates, 2014 28
Octapharma AG - Dormant Developmental Projects,2014 30
Octapharma AG, Subsidiaries 32
Octapharma AG, Key Manufacturing Facilities 35

List of Figures
Octapharma AG - Pipeline by Top 10 Indication, 2014 7
Octapharma AG - Pipeline by Stage of Development, 2014 9
Octapharma AG - Monotherapy Products in Pipeline, 2014 10
Octapharma AG - Pipeline by Top 10 Target, 2014 24
Octapharma AG - Pipeline by Top 10 Route of Administration, 2014 25
Octapharma AG - Pipeline by Top 10 Molecule Type, 2014 26
Octapharma AG - Pipeline Products by Top 10 Mechanism of Action, 2014 27

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax